Functional mechanism of the enhancement of 5-fluorouracil sensitivity by TUSC4 in colon cancer cells

Oncology Letters
Ming-Na LiuBing-Rong Liu

Abstract

5-Fluorouracil (5-FU) is the chemotherapeutic drug of choice for the treatment of metastatic colorectal cancer (CRC). Tumor suppressor candidate 4 (TUSC4), also referred to as nitrogen permease regulator-like 2 (NPRL2), is located at chromosome 3p21.3 and expressed in numerous normal tissues, including the heart, liver, skeletal muscle, kidney, and pancreas. The aim of the present study was to investigate the functional mechanism by which TUSC4 affects sensitivity to 5-FU and to determine its clinical significance in CRC. The results of the present study demonstrated that TUSC4 overexpression increases the sensitivity of HCT116 cells to 5-FU. The IC50 of 5-FU was reduced in cells transduced with TUSC4 compared with negative control (NC) cells, and the effect of TUSC4 on 5-FU sensitivity was time dependent. Following TUSC4 transduction in HCT116 cells, a proportion of the cells were arrested in the G1 phase of the cell cycle, and a reduction in the S phase population was observed. Flow cytometry analysis revealed that TUSC4 transduction and 5-FU treatment increased apoptosis compared with NC cells. The mechanism through which TUSC4 overexpression enhances 5-FU sensitivity involves the downregulation of the function of the PI3K/A...Continue Reading

References

Apr 29, 2000·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·G J PetersH M Pinedo
Dec 2, 2000·Nature·B B Zhou, S J Elledge
Oct 18, 2001·Anti-cancer Drugs·P G Johnston, S Kaye
Feb 25, 2005·Annals of Oncology : Official Journal of the European Society for Medical Oncology·S VignotE Raymond
Dec 17, 2005·Current Opinion in Oncology·Yardena Samuels, Kajsa Ericson
Oct 24, 2006·Biochimica Et Biophysica Acta·Pedro M BorralhoCecília M P Rodrigues
Jul 7, 2007·Cancer Cell·David A Guertin, David M Sabatini
Aug 19, 2007·Cancer Research·Gemma ArmengolSantiago Ramón y Cajal
Jan 23, 2008·Expert Opinion on Therapeutic Targets·Sauveur-Michel MairaCarlos Garcia-Echeverria
Mar 12, 2008·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Josep TaberneroJosé Baselga
Jan 16, 2009·Biochemical Society Transactions·Christopher G Proud
Feb 16, 2010·Nutrition and Cancer·Bhaumik B Patel, Adhip P N Majumdar
Apr 28, 2010·Journal of the American College of Surgeons·Sara M JohnsonB Mark Evers
Jan 13, 2012·CA: a Cancer Journal for Clinicians·Rebecca SiegelAhmedin Jemal

❮ Previous
Next ❯

Related Concepts

Related Feeds

AKT Pathway

This feed focuses on the AKT serine/threonine kinase, which is an important signaling pathway involved in processes such as glucose metabolism and cell survival.

Apoptosis in Cancer

Apoptosis is an important mechanism in cancer. By evading apoptosis, tumors can continue to grow without regulation and metastasize systemically. Many therapies are evaluating the use of pro-apoptotic activation to eliminate cancer growth. Here is the latest research on apoptosis in cancer.

Apoptosis

Apoptosis is a specific process that leads to programmed cell death through the activation of an evolutionary conserved intracellular pathway leading to pathognomic cellular changes distinct from cellular necrosis